Payment overview · 2025
General Payments
$49.58
3 reported records · 3 companies
Healthcare provider profile · identity verified
Matthew Wade Floersch, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MANHATTAN, KS · NPI 1114993698
Verified facts
What the public records show
CMS Open Payments records show Matthew Wade Floersch, M.D. received $49.58 in general payments during 2025 across 3 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.77 | 39.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.66 | 31.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.15 | 28.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.58 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 767 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 741 | 143 |
| Furosemide | Furosemide | 515 | 87 |
| Spironolactone | Spironolactone | 417 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 78 |
| Omeprazole | Omeprazole | 329 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 75 |
| Eliquis | Apixaban | 312 | 37 |
| Losartan Potassium | Losartan Potassium | 310 | 69 |
| Lisinopril | Lisinopril | 306 | 78 |
| Sertraline Hcl | Sertraline Hcl | 299 | 57 |
| Gabapentin | Gabapentin | 283 | 53 |
| Mirtazapine | Mirtazapine | 260 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 55 |
| Montelukast Sodium | Montelukast Sodium | 243 | 65 |
| Donepezil Hcl | Donepezil Hcl | 237 | 42 |
| Allopurinol | Allopurinol | 205 | 40 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 201 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 48 |
| Divalproex Sodium | Divalproex Sodium | 192 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 29 |
| Simvastatin | Simvastatin | 185 | 43 |
| Alendronate Sodium | Alendronate Sodium | 170 | 37 |
| Metformin Hcl Er | Metformin Hcl | 167 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 40 |
| Tramadol Hcl | Tramadol Hcl | 145 | 33 |
| Metformin Hcl | Metformin Hcl | 138 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 28 |
| Memantine Hcl | Memantine Hcl | 135 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 29 |
| Potassium Chloride | Potassium Chloride | 132 | 22 |
| Ozempic | Semaglutide | 125 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 25 |
| Famotidine | Famotidine | 109 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 36 |
| Carvedilol | Carvedilol | 105 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 18 |
| Warfarin Sodium | Warfarin Sodium | 100 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 23 |
| Jardiance | Empagliflozin | 83 | 13 |
| Xarelto | Rivaroxaban | 80 | 11 |
| Atenolol | Atenolol | 76 | 15 |
| Digoxin | Digoxin | 73 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 17 |
| Meloxicam | Meloxicam | 68 | 19 |
| Trazodone Hcl | Trazodone Hcl | 63 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 12 |
| Colestipol Hcl | Colestipol Hcl | 58 | 14 |
| Lorazepam | Lorazepam | 57 | 20 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Prednisone | Prednisone | 54 | 24 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Clonazepam | Clonazepam | 50 | suppressed |
| Ramipril | Ramipril | 49 | suppressed |
| Fentanyl | Fentanyl | 47 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Finasteride | Finasteride | 43 | 12 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Metolazone | Metolazone | 43 | suppressed |
| Multaq | Dronedarone Hcl | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 13 |
| Glimepiride | Glimepiride | 40 | 11 |
| Telmisartan | Telmisartan | 40 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Nystatin | Nystatin | 38 | 24 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Amantadine | Amantadine Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Trimethoprim | Trimethoprim | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 24 | 20 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Primidone | Primidone | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.58 · 3 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, CAPLYTA, JARDIANCE, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error